Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Immunol Methods ; 460: 63-71, 2018 09.
Article in English | MEDLINE | ID: mdl-29935209

ABSTRACT

BACKGROUND: Eculizumab (ECU) blocks complement C5 cleavage, preventing the formation of C5a and the cytolytic effects of the membrane attack complex. The presence of ECU in blood impacts routine complement tests used to monitor treatment. METHODS: Residual serum samples with normal total complement (CH50) and residual citrate plasma with normal PT/APTT were spiked with ECU at varied concentrations ranging from 25 to 600 µg/mL. In addition, seventy-one samples from patients on ECU were obtained. Artificial and patient samples were analyzed for CH50 and C5 function (Wako Diagnostics), C5 concentration (Quidel), AH50 (Wieslab ELISA) and sMAC (Quidel). ECU concentration was measured by mass spectrometry for all patients. RESULTS: Complement blockage by ECU was evident in spiked artificial samples. At 25 µg/mL ECU, partial complement blockage was observed in CH50, AH50 and C5 function in serum. Complete blockage defined by undetectable AH50 (<10%) occurred at 100 µg/mL ECU. C5 concentrations remained the same regardless of ECU. sMAC results stayed around 81% of baseline in serum and 47% in citrate plasma with 50µg/mL ECU. Patient samples had ECU ranging from <5 to 1220 µg/mL. In all patients with ECU >100 µg/mL, C5 function was <29 U/mL. CONCLUSIONS: The spiked sera and patient samples showed complement blockage with CH50, AH50 and C5 function assays when ECU >100 µg/mL. CH50, AH50 or C5 function assays can serve as indicators for the pharmacodynamic effects of eculizumab. Allied to ECU concentration, laboratory studies may be helpful to tailor therapy.


Subject(s)
Antibodies, Monoclonal, Humanized , Complement Activation/drug effects , Complement C5/metabolism , Complement Membrane Attack Complex/metabolism , Immunologic Tests , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/pharmacokinetics , Atypical Hemolytic Uremic Syndrome/blood , Atypical Hemolytic Uremic Syndrome/drug therapy , Female , Humans , Male
2.
Clin Chem Lab Med ; 56(7): 1071-1080, 2018 06 27.
Article in English | MEDLINE | ID: mdl-29455184

ABSTRACT

BACKGROUND: Cerebrospinal fluid (CSF) used in immunoglobulin gamma (IgG) index testing and oligoclonal bands (OCBs) are common laboratory tests used in the diagnosis of multiple sclerosis. The measurement of CSF free light chains (FLC) could pose as an alternative to the labor-intensive isoelectric-focusing (IEF) gels used for OCBs. METHODS: A total of 325 residual paired CSF and serum specimens were obtained after physician-ordered OCB IEF testing. CSF kappa (cKFLC) and lambda FLC (cLFLC), albumin and total IgG were measured. Calculations were performed based on combinations of analytes: CSF sum of kappa and lambda ([cKFLC+cLFLC]), kappa-index (K-index) ([cKFLC/sKFLC]/[CSF albumin/serum albumin]), kappa intrathecal fraction (KFLCIF) {([cKFLC/sKFLC]-[0.9358×CSF albumin/serum albumin]^[0.6687×sKFLC]/cKFLC)} and IgG-index ([CSF IgG/CSF albumin]/[serum IgG/serum albumin]). RESULTS: Patients were categorized as: demyelination (n=67), autoimmunity (n=53), non-inflammatory (n=50), inflammation (n=38), degeneration (n=28), peripheral neuropathy (n=24), infection (n=13), cancer (n=11), neuromyelitis optica (n=10) and others (n=31). cKFLC measurement used alone at a cutoff of 0.0611 mg/dL showed >90% agreement to OCBs, similar or better performance than all other calculations, reducing the number of analytes and variables. When cases of demyelinating disease were reviewed, cKFLC measurements showed 86% clinical sensitivity/77% specificity. CONCLUSIONS: cKFLC alone demonstrates comparable performance to OCBs along with increased sensitivity for demyelinating diseases. Replacing OCB with cKFLC would alleviate the need for serum and CSF IgG and albumin and calculated conversions. cKFLC can overcome challenges associated with performance, interpretation, and cost of traditional OCBs, reducing costs and maintaining sensitivity and specificity supporting MS diagnosis.


Subject(s)
Immunoglobulin kappa-Chains/cerebrospinal fluid , Immunoglobulin lambda-Chains/cerebrospinal fluid , Multiple Sclerosis/diagnosis , Oligoclonal Bands/cerebrospinal fluid , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Child , Child, Preschool , Cohort Studies , Female , Humans , Immunoglobulin kappa-Chains/blood , Immunoglobulin lambda-Chains/blood , Infant , Male , Middle Aged , Nephelometry and Turbidimetry , Sensitivity and Specificity , Young Adult
3.
Clin Chem Lab Med ; 54(6): 1085-93, 2016 Jun 01.
Article in English | MEDLINE | ID: mdl-26812875

ABSTRACT

BACKGROUND: The use of therapeutic recombinant monoclonal antibodies (mAbs) has triggered concerns of mis-diagnosis of a plasma cell dyscrasia in treated patients. The purpose of this study is to determine if infliximab (INF), adalimumab (ADA), eculizumab (ECU), vedolizumab (VEDO), and rituximab (RITU) are detected as monoclonal proteins by serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE). METHODS: Pooled normal sera were spiked with various concentrations (ranging from trough to peak) of INF, ADA, ECU, VEDO and RITU. The peak concentration for VEDO and RITU was also added to samples with known monoclonal gammopathies. All samples were analyzed by SPEP (Helena Laboratories) and IFE (Sebia); sera containing peak concentrations of mAbs were reflexed to electrospray-time-of-flight mass spectrometry (AbSciex Triple TOF 5600) for the intact light chain monoclonal immunoglobulin rapid accurate mass measurement (miRAMM). RESULTS: For all mAbs tested, no quantifiable M-spikes were observed by SPEP at any concentration analyzed. Small γ fraction abnormalities were noted on SPEP for VEDO at 300 µg/mL and RITU at 400 µg/mL, with identification of small IgG κ proteins on IFE. Using miRAMM for peak samples, therapeutic mAbs light chain accurate masses were identified above the polyclonal background and were distinct from endogenous monoclonal gammopathies. CONCLUSIONS: MAbs should not be easily confounded with plasma cell dyscrasias in patients undergoing therapy except when a SPEP and IFE are performed within a couple of days from infusion (peak). In ambiguous cases the use of the miRAMM technology could precisely identify the therapeutic mAb distinct from any endogenous monoclonal protein.


Subject(s)
Antibodies, Monoclonal/blood , Paraproteinemias/diagnosis , Antibodies, Monoclonal/therapeutic use , Blood Protein Electrophoresis , Diagnostic Errors/prevention & control , Humans , Immunoelectrophoresis , Immunoglobulin G/blood , Immunoglobulin kappa-Chains/blood , Immunoglobulin lambda-Chains/blood , Inflammation/drug therapy
4.
Clin Lab ; 61(5-6): 643-6, 2015.
Article in English | MEDLINE | ID: mdl-26118201

ABSTRACT

BACKGROUND: Differentiation between glomerular and non-glomerular hematuria by observation of the erythrocyte morphology using phase-contrast is a time-consuming and labor-intensive procedure that requires skilled personnel. This paper has the purpose to evaluate the performance of UriSed (also called sediMAX in some countries) as an alternative to the phase-contrast microscopic analysis of erythrocyte morphology. METHODS: 312 urine samples with hematuria were analyzed by UriSed and by phase-contrast microscopy. Based on the presence of codocytes and/or acanthocytes, samples were classified as non-glomerular and glomerular. Kappa correlation was used to assess the agreement between both methods. RESULTS: Our data showed excellent agreement between erythrocyte morphology analyzed by both methods (r = 0.974, kappa = 0.9484, p < 0.001) with only 8 samples presenting discordant results. CONCLUSIONS: UriSed proved to be a precise and accurate alternative to the gold standard phase-contrast microscopy.


Subject(s)
Erythrocytes/pathology , Hematuria/pathology , Kidney Diseases/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Humans , Infant , Male , Microscopy, Phase-Contrast , Middle Aged , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...